Gericke N200 Nibbler Provides Size Reduction - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gericke N200 Nibbler Provides Size Reduction


Pharmaceutical Technology
Volume 38, Issue 1, pp. 16
The N200 Pharma Nibbler offers a 200 mm diameter inlet and throughput of 1.500 (1/h), providing an alternative to hammer mills and more complex equipment for consistent size reduction of materials and agglomerates found in pharmaceutical production. Products enter the inlet either by a dump or controlled feed where a paddle assembly then rotates the product inside the size reduction chamber at a slow rotational speed. Attrition milling shears the product through the screen where it is discharged through the single outlet. The N200 Nibbler model features high capacity size reduction, a compact design, low power consumption and noise levels, minimum product temperature rise and fines generation, consistent particle size, and low rotational speed. It is suitable for glove box mounting and offers easy basket removal to provide improved access for cleaning.

Powder Technologies

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here